Developing a vaccine to protect against HIV/AIDS using specialized liposomes
HIV-1 vaccine design emphasizing bnAb targets on membrane Env liposomes
This study is testing a new type of vaccine that helps the body make strong defenses against HIV by using special particles that look like the virus, and it's aimed at improving future HIV vaccines for everyone.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Scripps Research Institute, the NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project ID | NIH-10578712 on NIH RePORTER |
What this research studies
This research focuses on creating a vaccine that stimulates the immune system to produce broadly neutralizing antibodies (bnAbs) against HIV/AIDS. The approach involves using membrane-embedded forms of the HIV-1 envelope glycoprotein presented on liposomes, known as m-Env liposomes (MELs). By immunizing rabbits and genetically modified mice with these MELs, the researchers aim to understand how different strategies can enhance the immune response to the virus. This innovative method seeks to improve the effectiveness of HIV vaccines by closely mimicking the natural structure of the virus.
Who could benefit from this research
Good fit: Ideal candidates for this research would include individuals at high risk for HIV infection or those who are currently HIV-negative but may benefit from preventive measures.
Not a fit: Patients who are already living with HIV/AIDS may not directly benefit from this research as it focuses on vaccine development for prevention.
Why it matters
Potential benefit: If successful, this research could lead to a more effective vaccine against HIV/AIDS, potentially reducing the incidence of the disease.
How similar studies have performed: Previous research has shown promise in using similar approaches to vaccine development, but this specific method using m-Env liposomes is relatively novel.
Where this research is happening
La Jolla, United States
- Scripps Research Institute, the — La Jolla, United States (Active)
Researchers
- Principal investigator: Zwick, Michael B — Scripps Research Institute, the
- Study coordinator: Zwick, Michael B
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.